Condition: Solid Tumor, Adult · Mesothelioma · NSCLC · Sponsor: Vivace Therapeutics, Inc
This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which no effective standard therapy is available.
This description comes directly from the study's public registry record.
Heather Fritz · 650-627-7437 · hfritz@inclin.com
Neelesh Sharma, MD · 732-476-4978 · nsharma@vivacetherapeutics.com
Always discuss trial participation with your own doctor first.
| UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco, California, United States | Recruiting |
| University of Chicago Medical Center | Chicago, Illinois, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| M Health Fairview University of Minnesota Medical Center | Minneapolis, Minnesota, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| NEXT Oncology | San Antonio, Texas, United States | Recruiting |
| Virginia Cancer Specialists, PC | Arlington, Virginia, United States | Recruiting |
| Monash Health | Clayton, Victoria, Australia | Recruiting |
| Peter MacCullum Cancer Centre | Melbourne, Victoria, Australia | Recruiting |
| Linear Clinical Research | Nedlands, Western Australia, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04665206